Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury

Neurocritical Care

Volumn 19, Issue 2, 2013, Pages 192-198

  Cousar, J'Mir L ^a   Conley, Yvette P ^b   Willyerd, F Anthony ^c   Sarnaik, Ajit A ^d   Puccio, Ava M ^e   Empey, Philip E ^b   Kochanek, Patrick M ^f   Bell, Michael J ^e   Okonkwo, David O ^e   Clark, Robert S B ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d University Pediatricians   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Blood brain barrier; Head trauma; Membrane transporter; Multidrug resistance protein; Multidrug resistance associated protein; P Glycoprotein

Indexed keywords

ABC TRANSPORTER; ATP BINDING CASSETTE TRANSPORTER C1; ATP BINDING CASSETTE TRANSPORTER C2; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLASGOW OUTCOME SCALE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RACE DIFFERENCE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRAUMATIC BRAIN INJURY;

ADOLESCENT; ADULT; AGED; BLOOD-BRAIN BARRIER; BRAIN INJURIES; FEMALE; GLASGOW COMA SCALE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOVERY OF FUNCTION; YOUNG ADULT;

EID: 84885185261     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9881-7     Document Type: Article

References (39)

1. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Center for Disease Control and Prevention, Nation Center for Injury Prevention and Control; 2010.
2. Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients with traumatic brain injury. Neurosurg Focus. 2010;28:E9.
3. Diaz-Arrastia R, Baxter VK. Genetic factors in outcome after traumatic brain injury: what the human genome project can teach us about brain trauma. J Head Trauma Rehabil. 2006;21:361-74.
4. Dardiotis E, Grigoriadis S, Hadjigeorgiou GM. Genetic factors influencing outcome from neurotrauma. Curr Opin Psychiatry. 2012;25:231-8.
5. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216-37.
6. Hartz AM, Bauer B. ABC transporters in the CNS - an inventory. Curr Pharm Biotechnol. 2011;12:656-73.
7. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132:2517-30.
8. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591-602.
9. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-8.
10. Siedlinski M, Boezen HM, Boer JM, Smit HA, Postma DS. ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet Genomics. 2009;19:675-84.
11. Ufer M, Mosyagin I, Muhle H, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C > T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009;19:353-62.
12. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442-8.
13. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit. 2007;29:305-12.
14. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure. 2008;17:524-30.
15. Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010;20:249-56.
16. International HapMap Project. http://www.hapmap.org. Accessed Mar 2011.
17. Howie BN, Carlson CS, Rider MJ, Nickerson DA. Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Hum Genet. 2006;120:58-68.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
19. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-4.
20. Marshall LF, Bowers-Marshall S, Klauber MR, et al. A new classification of head injury based on computerized tomography. J Neurosurg. 1991;75:S14-20.
21. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol. 2001;54:979-85.
22. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794:860-71.
23. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-8.
24. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liow HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics. 2007;8:1151-8.
25. Kwan P, Baum L, Wong V, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007;11:112-7.
26. Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:487-8.
27. Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin Drug Deliv. 2006;3:23-35.
28. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells. Pharmacogenetics. 2001;11:293-8.
29. Owen A, Goldring C, Morgan P, Park BK, Chadwick D, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol. 2005;59:365-70.
30. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia. 2009;50:898-903.
31. Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011;12:713-25.
32. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol. 2011;201:261-83.
33. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21:152-61.
34. van Assema DM, Lubberink M, Bauer M, et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain. 2012;135:181-9.
35. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10:1295-312.
36. Jedlitschky G, Grube M, Mosyagin I, et al. Targeting CNS transporters for treatment of neurodegenerative diseases. Curr Pharm Des. 2013. doi: 10.2174/13816128113199990460.
37. Ito K, Olsen SL, Qiu W, et al. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem. 2001;276:15616-24.
38. Deeley RG, Cole SPC. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006;580:1103-11.
39. Budulac SE, Postma DS, Hiemstra PS, et al. Multidrug resistance- associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPD. Respir Res. 2010;11:60.